Fluoroquinolone-associated myasthenia gravis exacerbation: evaluation of postmarketing reports from the US FDA adverse event reporting system and a literature review.

April
SunMonTueWedThuFriSat
303112345678910111213141516171819202122232425262728293012345678910
April
SunMonTueWedThuFriSat
303112345678910111213141516171819202122232425262728293012345678910
Copyright © Ark Medical Solutions Inc. All Rights Reserved.